Rhodamine based plasmid DNA nanoparticles for mitochondrial gene therapy

Area of Science:

• Biochemistry
• Nanotechnology
• Genetics

Background:

• Mitochondrial cytopathies lack effective treatments, necessitating novel therapeutic strategies.
• Mitochondrial gene therapy presents a promising avenue for restoring metabolic function in related diseases.

Purpose of the Study:

• To develop and evaluate novel mitochondrial-targeted plasmid DNA nanoparticles for gene therapy.
• To assess the biocompatibility, cellular uptake, and mitochondrial targeting efficiency of these nanocarriers.

Main Methods:

• Incorporation of rhodamine 123 into plasmid DNA nanoparticles to confer mitochondria affinity.
• Characterization of nanoparticle size, biocompatibility, and pDNA protection from nucleases.
• Assessment of cellular internalization and mitochondrial targeting via fluorescence confocal microscopy and p53 protein expression analysis.

Main Results:

• Developed biocompatible nanoparticles with suitable sizes for gene therapy.
• Demonstrated efficient cellular uptake and successful targeted delivery of pDNA to mitochondria.
• Confirmed mitochondrial targeting by observing p53 protein expression mediated by rhodamine nanoparticles.

Conclusions:

• The developed rhodamine-123-containing nanoparticles are effective gene delivery systems.
• These nanoparticles exhibit significant mitochondrial targeting capabilities, relevant for mitochondrial gene therapy.
• The study provides a foundation for engineering advanced vectors for treating mitochondrial diseases.